Onkologie. 2016:10(6):256-262 | DOI: 10.36290/xon.2016.054

Malignant melanoma and new options of treatment

Viera Bajčiová
Klinika dětské onkologie FN a LF MU Brno

Treatment of advanced and metastatic melanoma has been revolutionezed over the last five years. After decades of stagnation and

searching the new targeted biology therapy and modern immunotherapy offers chance of long term survival for almost 30 % of

patients. The search for predictive biomarkers, duration of effective treatment, the optimal strategy for wild-type melanoma remains

the goals of further research and future perspectives. Search for different variants of combined therapy is the subject of clinical trials.

Keywords: malignant melanoma, targeted biology therapy, immunotherapy

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bajčiová V. Malignant melanoma and new options of treatment. Onkologie. 2016;10(6):256-262. doi: 10.36290/xon.2016.054.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sullivan RJ, Flaherty KT. New strategies in melanoma: entering the era of combinatorial therapy. Clin Cancer Res 2015; 21(11): 2424-2435. Go to original source... Go to PubMed...
    2. Berrocal A, Espinosa E, Marín S, et al. Spanish multidisciplinary melanoma group (GEM) guidelines for the management of patients with advanced melanoma. Eur J Dermatol 2015; 25(5): 392-403. Go to original source... Go to PubMed...
    3. Krajsová I. Kožní melanom: cílená léčba a imunoterapie. Onkologická Revue 2015: 30-33.
    4. Fait V, Henko V, Šimůnek R. Chirurgické postupy v léčbě maligního melanomu. Farmakoterapie 2015: 26-31.
    5. Corrie P, Hategan M, Fife K, et al. Management of melanoma. British Med Bulletin 2014; 111: 149-162. Go to original source... Go to PubMed...
    6. Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26(Suppl 5): 126-132. Go to original source... Go to PubMed...
    7. Vošmik M. Možnosti radioterapie v léčbě maligního melanomu. Farmakoterapie 2015: 20-25.
    8. Lakomý R, Poprach A. Cílená léčba pokročilého maligního melanomu. Farmakoterapie 2015: 38-42.
    9. Kubala E. Význam genových mutací pro léčbu melanomu (mutace BRAF). Farmakoterapie 2015: 16-19.
    10. Tawbi H, Nimmagadda N. Targeted therapy in melanoma. Biologics: Targets and therapy 2009; 3: 475-484. Go to original source...
    11. Goldinger SM, Murer C, Stieger P, et al. Targeted therapy in melanoma - the role of BRAF, RAS and KIT mutation. EJC Suppl 2013; 11(2): 92-96. Go to original source... Go to PubMed...
    12. Grimaldi AM, Simone E, Festino L, et al. Novel mechanisms and therapeutic approaches in melanoma: targeting MAPK pathway. Discov Med 2015; 19(107): 455-461. Go to PubMed...
    13. Johnson DB, Lovly CHM, Lavin M, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res 2015; 3(3): 288-295. Go to original source... Go to PubMed...
    14. Pho L, Grossmann D, Leachman SA. Melanoma genetic: a review of genetic factors and clinical phenotypes in familial melanoma. Current Opin Oncol 2006; 18: 173-179. Go to original source... Go to PubMed...
    15. Johnson DB, Sosman JA. Therapeutic advances and treatment options in metastatic melanoma. JAMA 2015; 1(3): 380-386. Go to original source...
    16. van Engen-van Grunsven ACH, Kusters-Vandevelde H, Groenen PJTA, et al. Update on moleculat pathology of cutaneous melanocytic lesions: what is new in diagnosis and molecular testing for treatment? Front Med (Laussane) 2014; 1: 39. Go to original source... Go to PubMed...
    17. Bajčiová V. Maligní melanom u dětí a dospívajících, Onkológia 2016; 11(1): 22-28.
    18. Improta G, Leone I, Donia M, et al. New developments in the management of advanced melanoma - role of pembrolizumab. Onco Targets and Therapy 2015; 8: 2535-2543. Go to original source... Go to PubMed...
    19. Alcalá AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 2012; 18(1): 33-39. Go to original source... Go to PubMed...
    20. Geserick P, Herlyn M, Leverkus M. On the TRIAL to overcome BRAF-inhibitor Resistence. J Investig Dermatol 2014; 134(2): 315-318. Go to original source... Go to PubMed...
    21. Munos-Couselo, E, García JS, Pérez-García JM. Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. Ann Transit Med 2015; 3(15): 207.
    22. Tran KA, Cheby MY, Mitra A, et al. MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Design, Development and Therapy 2016; 10: 43-52. Go to original source... Go to PubMed...
    23. Villanueva J, Kultur A, Herlyn M. Resistaence to BRAF inhibitors, unraveling mechanisms and future treatment options. Cancer Re 2011; 71(23): 7137-7140. Go to original source... Go to PubMed...
    24. Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 2016; 8(1): 48-56. Go to original source... Go to PubMed...
    25. Atkins MB, Sznol M. Cancer immunotherapy: past progress and future directions. Ann Oncol 2015; 42(4): 518-522. Go to original source... Go to PubMed...
    26. Rozsypalová A, Buchler T. Role CTLA-4 a PD-1 v regulaci imunitní odpovědi. Onkologická revue 2015; 10-12.
    27. Spain L, Larkin J. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opin Biol Ther 2016; 16(3): 389-396. Go to original source... Go to PubMed...
    28. Olszanski AJ. Current and future role of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Pharm 2014; 20(4): 346-356. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.